Covaxin Cleared For 6-12 Age Group, Corbevax For Those Aged 5-12

In response to an increase in Covid cases in schools, the Drugs Controller General of India (DCGI) today granted Bharat Biotech’s Covaxin restricted use authorization for children aged 6 to 12.
The DCGI gave its approval following recommendations from the Central Drugs Standard Control Organisation’s Subject Expert Committee (SEC) on COVID-19 (CDSCO).

For the first two months, the DCGI has directed the vaccine maker to submit safety data, including data on adverse events, with due analysis every 15 days. Following that, Bharat Biotech will be required to submit data on a monthly basis for up to five months.On December 24, 2021, the DCGI granted Covaxin Emergency Use Listing for the age group of 12 to 18 years. It is currently being given to those between the ages of 15 and 18.

Corbevax, a Covid-19 vaccine developed by Hyderabad-based Biological E, has also been given emergency use authorization by the DCGI for children aged 5 to 12. The Corbevax vaccine is currently being given to children aged 12 to 14.

In addition, Zydus Cadila’s vaccine ZycovD has been approved for use in children aged 12 and up in a two-dose regimen.
Covid-19 vaccinations for teenagers aged 15 to 18 years old began on January 3 this year. Last month, the drive was expanded to include children aged 12 and up. On April 1 of last year, India began a vaccination campaign for all people over the age of 45. From May of last year, the government decided to expand its vaccination campaign by allowing anyone over the age of 18 to be inoculated against the viral disease.

Picture Courtesy: Google/Images are subject to copyright